Sunday, March 16, 2025 | 06:53 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Lupin recieves USFDA nod to market generic anthelmintic tablets

According to IQVIA MAT April 2020 data, Albendazole tablets had an annual sales of around $34 million in the US, Lupin said

Lupin
Premium

Shares of Lupin closed at Rs 920.45 per scrip on the BSE

BS Web TeamPTI New Delhi
Drug firm Lupin on Thursday said it had received an approval from the US health regulator to market its generic anthelmintic Albendazole tablets.

The company has received approval to market its Albendazole tablets USP, 200 mg, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.

The product is a generic version of Impax Laboratories Inc's Albenzatablets in the same strength, it added.


According to IQVIA MAT April 2020 data, Albendazole tablets had an annual sales of around $34 million in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in